Selskabets formål er at drive parallelhandel med lægemidler, handel med medicin vedrørende ikke-registrerede lægemidler og handel med lægemidler i forbindelse med kliniske forsøg samt hermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 1.8 mia. | 7.8 mio. | 494.7 mio. | 98.5 mio. | 1590 | |
CVR: 28111576
Secondary names: Originalis A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
ABACUS MEDICINE A/S demonstrates a solid financial trajectory, with revenue increasing from 940.7 million DKK in 2021 to 1.82 billion DKK in 2025. However, profit has fluctuated, peaking at 20 million DKK in 2023 before declining to 7.8 million DKK in 2025, indicating potential margin pressures. The company's equity has steadily improved, reaching 98.5 million DKK in 2025, reflecting a strengthening balance sheet. Positioned within the wholesale distribution of pharmaceuticals and healthcare products, ABACUS MEDICINE is growing but may need to address profitability challenges to sustain its upward momentum.
AI-generated summary
Companies in the same industry and area
CVR 41183144
CVR 35451307
CVR 37626619
CVR 36392398
CVR 14479880
companydata.dk